
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.230
Open
2.160
VWAP
2.16
Vol
151.61K
Mkt Cap
171.49M
Low
2.100
Amount
327.66K
EV/EBITDA(TTM)
--
Total Shares
80.88M
EV
2.86M
EV/OCF(TTM)
--
P/S(TTM)
--
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Show More
3 Analyst Rating

170.00% Upside
Wall Street analysts forecast IMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMAB is 5.67 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

170.00% Upside
Current: 2.100

Low
5.00
Averages
5.67
High
7.00

170.00% Upside
Current: 2.100

Low
5.00
Averages
5.67
High
7.00
Lucid Capital
initiated
$5
2025-05-28
Reason
Lucid Capital
Price Target
$5
2025-05-28
initiated
Reason
Lucid Capital initiated coverage of I-Mab with a Buy rating and $5 price target. I-Mab is a clinical-stage biotechnology company focused on precision therapeutics for the treatment of cancer, the analyst tells investors in a research note. The firm believes the company's CLDN18.2 x 4-1BB bispecific antibody, givastomig, could be a significant value driver for shares, approaching the top-line Phase 1b combination dose escalation and dose expansion data.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Maintains
$8 → $7
2025-04-04
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$8 → $7
2025-04-04
Maintains
Strong Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$4
2025-04-04
Reason
Needham
Gil Blum
Price Target
$4
2025-04-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$8
2024-11-15
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$8
2024-11-15
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$8
2024-09-17
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$8
2024-09-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$8
2024-08-29
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$8
2024-08-29
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for I-Mab (IMAB.O) is -10.29, compared to its 5-year average forward P/E of -18.86. For a more detailed relative valuation and DCF analysis to assess I-Mab 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-18.86
Current PE
-10.29
Overvalued PE
10.15
Undervalued PE
-47.88
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
5.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
71.11
Undervalued EV/EBITDA
-60.30
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
14.55
Current PS
0.00
Overvalued PS
49.87
Undervalued PS
-20.77
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
-38.07%
-5.27M
Operating Profit
FY2025Q1
YoY :
-66.56%
-3.15M
Net Income after Tax
FY2025Q1
YoY :
-77.78%
-0.02
EPS - Diluted
FY2020Q4
YoY :
-581.77%
152.96M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
2.0
Volume
1
6-9
Months
928.6K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IMAB News & Events
Events Timeline
2025-07-17 (ET)
2025-07-17
07:05:24
I-Mab entered into agreement to acquire 100% ownership of Bridge Health Biotech

2025-07-02 (ET)
2025-07-02
11:20:43
I-Mab presents Gibastomig Phase 1b dose escalation data

2025-06-30 (ET)
2025-06-30
16:06:57
I-Mab publishes givastomig monotherapy data in Clinical Cancer Research

Sign Up For More Events
Sign Up For More Events
News
8.5
07-17NewsfilterPinnedI-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
4.0
07-09BenzingaNeedham Reiterates Buy on I-MAB, Maintains $5 Price Target
9.0
07-02NewsfilterI-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Sign Up For More News
People Also Watch

OSS
One Stop Systems Inc
5.900
USD
-3.12%

ENTX
Entera Bio Ltd
2.050
USD
+0.49%

ELVA
Electrovaya Inc
3.690
USD
-2.64%

MVO
MV Oil Trust
5.860
USD
+1.56%

IMUX
Immunic Inc
0.964
USD
+3.66%

DBVT
Dbv Technologies SA
10.000
USD
+2.99%

VMCA
Valuence Merger Corp I
0
USD
-0.17%

AIRG
Airgain Inc
4.800
USD
+11.63%

VOC
VOC Energy Trust
3.100
USD
+4.38%

AZI
Autozi Internet Technology (Global) Ltd
0.257
USD
+3.63%
FAQ

What is I-Mab (IMAB) stock price today?
The current price of IMAB is 2.1 USD — it has decreased -2.78 % in the last trading day.

What is I-Mab (IMAB)'s business?

What is the price predicton of IMAB Stock?

What is I-Mab (IMAB)'s revenue for the last quarter?

What is I-Mab (IMAB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for I-Mab (IMAB)'s fundamentals?

How many employees does I-Mab (IMAB). have?
